SG Americas Securities LLC Boosts Stake in Genmab A/S (NASDAQ:GMAB)

SG Americas Securities LLC raised its position in Genmab A/S (NASDAQ:GMAB) by 82.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,396 shares of the company’s stock after purchasing an additional 11,949 shares during the quarter. SG Americas Securities LLC’s holdings in Genmab A/S were worth $551,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of GMAB. Two Sigma Advisers LP raised its position in Genmab A/S by 84.1% in the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock valued at $14,996,000 after purchasing an additional 280,900 shares during the period. FMR LLC boosted its position in shares of Genmab A/S by 13.5% in the third quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after buying an additional 33,076 shares during the period. Oppenheimer Asset Management Inc. grew its stake in shares of Genmab A/S by 6.5% in the third quarter. Oppenheimer Asset Management Inc. now owns 232,243 shares of the company’s stock valued at $5,662,000 after buying an additional 14,165 shares in the last quarter. Natixis Advisors LLC raised its holdings in shares of Genmab A/S by 29.8% during the 3rd quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock valued at $5,036,000 after buying an additional 47,437 shares during the period. Finally, US Bancorp DE lifted its position in Genmab A/S by 16.0% during the 3rd quarter. US Bancorp DE now owns 171,669 shares of the company’s stock worth $4,185,000 after acquiring an additional 23,723 shares in the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. BMO Capital Markets reaffirmed an “outperform” rating and issued a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research note on Thursday, January 23rd. Redburn Atlantic started coverage on shares of Genmab A/S in a research report on Tuesday, October 8th. They issued a “buy” rating for the company. Finally, Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Stock Performance

Shares of Genmab A/S stock opened at $19.67 on Friday. Genmab A/S has a 1 year low of $19.02 and a 1 year high of $31.88. The firm’s 50-day simple moving average is $21.04 and its 200-day simple moving average is $23.76. The firm has a market cap of $13.02 billion, a PE ratio of 19.10, a price-to-earnings-growth ratio of 0.55 and a beta of 0.97.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.03). The firm had revenue of $816.10 million for the quarter, compared to analyst estimates of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same quarter in the previous year, the company earned $0.47 EPS. On average, equities analysts predict that Genmab A/S will post 1.25 earnings per share for the current year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.